Purchase Order 36C26121P0020
Award Date 10/1/20
Potential Completion Date 9/30/21
Potential Value $116K
Federal Agency
Awardee
Ultimate Awardee
NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Earth City, MO 63045, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a firm fixed price purchase order contract awarded by the Department of Veterans Affairs Veterans Health Administration to Foundation Care LLC, a specialty pharmacy, to provide the drug Iclusig (ponatinib). The contract has a potential value of $110,424.15 and a completion date of September 30, 2022. Foundation Care LLC is a subsidiary of Centene Corporation, a for-profit organization. The contract does not have a set-aside designation. Through this and other federal contract awards,...
- Foundation Care LLC, a specialty pharmacy and subsidiary of Centene Corporation, was awarded a firm fixed-price purchase order by Veterans Integrated Service Network 2 (VISN 2) on February 4, 2026, to supply 60 units of Iclusig 15mg, a specialized chemotherapy medication used to treat blood disorders including chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. The contract carries a ceiling value of $28,771.50 with an ultimate completion date of May 4,...
- Foundation Care LLC, a for-profit specialty pharmacy and subsidiary of Centene Corporation, has been awarded a $24,538.70 firm fixed price purchase order contract by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 located in Palo Alto, California. The contract is for the provision of Iclusig (ponatinib), a medication used to treat certain types of leukemia and blood disorders. Performance will take place in Palo Alto and be completed by...
- Foundation Care LLC, a for-profit specialty pharmacy and subsidiary of Centene Corporation, has been awarded a $13,956.72 firm-fixed-price purchase order contract by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 6. The contract is for the provision of Iclusig 15 mg tablets to the Earth City, Missouri VA medical center, with a period of performance through February 29, 2024. Iclusig is used to treat chronic myeloid leukemia and...
- This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 8 to Foundation Care LLC, a for-profit specialty pharmacy and subsidiary of Centene Corporation. The $5,390.00 contract is for the delivery of pain management components, with an ultimate completion date of November 15, 2015. The contract does not have a set-aside designation. Foundation Care LLC is a critical supplier of specialized pharmaceutical products,...
- This federal contract award is for the delivery of the cancer drug Iclusig (ponatinib) to the Department of Veterans Affairs Veterans Health Administration. The contract was awarded to the prime contractor Ariad Pharmaceuticals, Inc., a foreign-owned, for-profit manufacturer of pharmaceutical products. The contract was not set aside and was awarded under the General Services Administration (GSA) Pharmaceuticals and Drugs schedule, which allows government agencies to purchase drugs and...
- This federal contract award is for the delivery of the specialty medication ICLUSIG 15 MG to the U.S. Department of Veterans Affairs (VA). The contract was awarded to Takeda Pharmaceuticals America, Inc., a foreign-owned, for-profit manufacturer of pharmaceutical products. The contract is a Delivery Order placed against Takeda's General Services Administration (GSA) Schedule 61-IB for Pharmaceuticals and Drugs. It is a firm-fixed-price contract with a ceiling value of $13,956.72 and an...
- This is a firm-fixed-price delivery order awarded by the U.S. Department of Veterans Affairs (VA) to Takeda Pharmaceuticals America, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract is for the supply of ICLUSIG 15 MG, a specialty oncology medication, to VA medical facilities. The contract has a ceiling value of $14,197.39 and a completion date of October 8, 2025. Takeda Pharmaceuticals America, Inc. holds a $123.5 million Blanket Purchase Agreement (BPA) with the VA...
- This is a federal contract awarded by the Department of Veterans Affairs (VA) to Takeda Pharmaceuticals America, Inc., a subsidiary of the Japanese pharmaceutical company Takeda Pharmaceutical Company Limited. The contract is for the supply of ICLUSIG (ponatinib), a specialty oncology medication used to treat certain types of leukemia. The contract is a Delivery Order placed against Takeda's General Services Administration (GSA) Schedule 61-IB for Pharmaceuticals and Drugs. It has a ceiling...
- The U.S. Department of Veterans Affairs (VA) awarded a $173,208.96 firm-fixed-price delivery order contract to Takeda Pharmaceuticals America, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, to provide bulk orders of the oncology medication ICLUSIG (ponatinib). The contract was issued against Takeda's existing General Services Administration (GSA) Schedule 61-IB for Pharmaceuticals and Drugs and supports the VA's provision of specialized cancer treatments to veterans nationwide....